A senior executive at Ceribell Inc. sold $44,424 worth of common stock in two separate transactions executed in late August, regulatory filings show.
David Foehr, the company’s Senior Vice President of Finance and Principal Accounting Officer, disposed of 1,852 shares between Aug. 21 and Aug. 24 at prices ranging from $23.95 to $24.02 per share. The first transaction involved 993 shares sold to cover tax obligations tied to the vesting of restricted stock units. The second, for 859 shares, was conducted under a pre-arranged Rule 10b5-1 trading plan, a mechanism designed to mitigate insider-trading risks.
Following the sales, Foehr retains direct ownership of 35,899 shares of Ceribell common stock. The company’s shares have advanced 109% over the past 12 months and are currently trading near the 52-week high of $25.33. Independent analysis cited by InvestingPro suggests the stock may be overvalued at current levels.
Ceribell reported second-quarter revenue of $28.1 million, a 33% year-over-year increase that outpaced the 29% growth recorded in the prior quarter. The company posted a loss per share of $0.51, exceeding market expectations. It added 32 new accounts during the period, slightly below Canaccord’s estimate of 36, though utilization within existing units remained strong.
Analysts have recently raised price targets on the stock. Canaccord lifted its target to $26 from $25, maintaining a buy rating, while BTIG increased its target to $30 from $28, citing Ceribell’s leadership in point-of-care rapid EEG technology. The company also secured recent FDA approval for pediatric and neonatal indications, supporting its expansion strategy.
